Laboratory reimbursement and other regulatory issues

The Centers for Medicare and Medicaid Services (CMS) is about to gather reimbursement data from laboratories to recalculate the clinical laboratory fee schedule.  The process and potential impact of this project, as well as  other new reimbursement models proposed by CMS will be discussed.  We will also update attendees on the FDA laboratory developed test guidance and controversy, describe the status of CLIA activities and analyze federal government policy developments pertaining to laboratory practice.